Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients : A Perspective from an Israeli Cross-Sector Collaboration
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 112(2022), 6 vom: 01. Dez., Seite 1156-1158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guy-Alfandary, Shiri [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.11.2022 Date Revised 29.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpt.2610 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340502088 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340502088 | ||
| 003 | DE-627 | ||
| 005 | 20231226005424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.2610 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340502088 | ||
| 035 | |a (NLM)35521643 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guy-Alfandary, Shiri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients |b A Perspective from an Israeli Cross-Sector Collaboration |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2022 | ||
| 500 | |a Date Revised 29.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Zhurat, Sasha |e verfasserin |4 aut | |
| 700 | 1 | |a Berlin, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a De Haan, Tal |e verfasserin |4 aut | |
| 700 | 1 | |a Gueta, Itai |e verfasserin |4 aut | |
| 700 | 1 | |a Shihmanter, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Golik, Ahuva |e verfasserin |4 aut | |
| 700 | 1 | |a Berkovitch, Matitiahu |e verfasserin |4 aut | |
| 700 | 1 | |a Eyal, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Lee H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 112(2022), 6 vom: 01. Dez., Seite 1156-1158 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2022 |g number:6 |g day:01 |g month:12 |g pages:1156-1158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.2610 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2022 |e 6 |b 01 |c 12 |h 1156-1158 | ||